Gene Logic, Inc.

Oncormed, Inc.

Other

Patricia D Murphy

Sheri J Olson

Bin Zeng

Christopher P Alvares

Brenda S Critz

Antonette C Allen

Denise B Schelter

Marga Belle White

Denise Bernadette Thurber

Tammy Lawrence

Antonette Preisinger Allen

Lisa K Sadzewicz

Tracy Staton Angelly

Jennifer Lee Lescallett

Mark B Rabin

Geoffrey M Jackson

Tara Eskandari

Brenda Schryer

Marga B White

Michael Park

Matthew Yoshikawa

Methods for identifying functional allele profiles of a given gene are disclosed. Functional allele profiles comprise the commonly occurring alleles in a population, and the relative frequencies at which such alleles of a given gene occur. Functional allele profiles are useful in treatment and diagnosis of diseases, for genetic and pharmacogenetic applications and for evaluating the degree to which the gene(s) are under selective pressure.

Method for determining the haplotype of a human BRCA1 gene

isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1, BRCA1, and BRCA1and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.

Coding sequences of the human BRCA1 gene

This invention is directed to the isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2), and BRCA1.sup.(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences. This invention is further related to protein therapy with BRCA.sup.(omi) proteins or their functional equivalent.

New mutations have been found in the BRCA1 gene. The mutations are located at nucleotide numbers 421-2, 815, 903, 926, 1506, 2034, 2428, 3888, 3904, 4164, 4643, 5053, 5150, 5210, or 5396+40 of the gene sequence of BRCA1. A process for identifying a sequence variation in a BRCA1 polynucleotide sequence is disclosed. The identification process includes allele specific sequence-based assays of known sequence variations. The methods can be used for efficient, and accurate detection of a mutation in a test BRCA1 gene sample.

Cancer susceptibility mutations of BRCA1

A step-wise integrated process for identifying sequence variations in polynucleotide sequences is disclosed. The identification process is composed of three stages, including allele specific hybridization assays of known sequence variations (Stage I), sequence variation locating assays (Stage II), and direct sequencing (Stage III). The methods can be used for efficient and accurate detection of mutations in any test gene sample.

Method for identifying variations in polynucleotide sequences

This invention is directed to three coding sequences of the BRCA1 gene. The three coding sequences, BRCA1.sup.(omi1), BRCA1.sup.(omi2) and BRCA1.sup.(omi3) as well as their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.

A child's toy which includes a plurality of detachable planar wall members. Each of the wall members has an exterior surface, an interior surface, and a plurality of side edges. The side edges define four corners. A plurality of VELCRO hook and loop type fastening strips are secured to each of the wall members. Each of the hook and loop type fastening strips on the wall members is adapted to mate with a complementary loop and hook type fastening strip on a different wall member in order to secure the wall members together. The child's toy includes at least one three dimensional toy figure releasably fastened to the interior surface of one of the wall members.

Detachable child's toy

A consensus DNA sequence has been determined for the BRCA1 gene. As has been seven polymorphic sites and their rates of occurrence in normal BRCA1 genes. The consensus gene BRCA1.sup.(omi) and the seven polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene, determine the presence of a normal gene, and of mutations, and to classify tumors.

Growing community of inventors

Slingerlands, NY, United States of America

Patricia D Murphy